일회용 바이오프로세싱 시장 : 제품별, 워크플로우 단계별, 바이오프로세스 방식별, 일회용 서브 어셈블리별, 제조 프로세싱별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Single-use Bioprocessing Market is projected to grow by USD 59.77 billion at a CAGR of 16.26% by 2032.

Single-use bioprocessing has moved from a niche manufacturing option to a mainstream operating model for biologics, vaccines, biosimilars, and advanced therapies. Disposable bioreactors, bags, tubing assemblies, connectors, filtration systems, sterile sampling technologies, and single-use sensors reduce cleaning validation burden, shorten changeover time, and support closed processing in GMP environments.

The industry is being shaped by the global expansion of monoclonal antibodies, mRNA platforms, cell and gene therapies, and intensified upstream and downstream processing. Adoption is also supported by documented reductions in water-for-injection demand, clean-in-place and steam-in-place infrastructure, and cross-contamination risk, while buyers continue to scrutinize extractables and leachables, resin security, supplier redundancy, particulate control, and plastic waste management.

Transformative Shifts in the Landscape

The single-use bioprocessing landscape is shifting toward modular, multiproduct, and digitally connected facilities. Manufacturers are increasingly combining single-use bioreactors, chromatography skids, sterile transfer systems, single-use mixers, depth filtration, and automation platforms to improve campaign flexibility and reduce facility buildout time.

A second major shift is the movement from open or semi-open workflows to closed, integrated processing. This transition is especially relevant for high-value biologics and personalized therapies where sterility assurance, rapid batch release, and manufacturing agility are critical. Standardization initiatives from industry groups, pharmacopoeias, and regulators are also improving confidence in materials characterization, component qualification, extractables and leachables testing, and supplier change control.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of single-use bioprocessing by improving process understanding, deviation detection, and capacity planning. AI-enabled analytics can support bioreactor control, predictive maintenance, raw-material forecasting, visual inspection, electronic batch record review, and process monitoring when implemented within validated, data-integrity-compliant quality systems.

The strongest near-term impact is in hybrid decision support rather than fully autonomous manufacturing. Digital twins, multivariate analysis, and machine learning models can help teams link sensor data, media performance, mixing conditions, cell-culture behavior, and filtration performance to critical quality attributes. However, adoption depends on robust model governance, audit trails, cybersecurity, human oversight, and alignment with FDA, EMA, ICH Q9, ICH Q10, ICH Q12, and GAMP principles.

Key Regional Insights

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, Singapore, and Australia expand biologics, biosimilar, vaccine, and advanced therapy manufacturing capacity. The region benefits from contract development and manufacturing momentum, public health investment, skilled bioprocessing talent, and cost-efficient production ecosystems, although firms must manage supplier qualification, resin traceability, cold-chain reliability, and regulatory harmonization across diverse markets.

North America remains a leading demand center due to the United States and Canada's concentration of biologics developers, CDMOs, cell therapy innovators, clinical trial infrastructure, and advanced manufacturing programs. Latin America, led by Brazil and Mexico, is adopting single-use technologies to strengthen vaccine resilience, public-sector biologics production, and biosimilar manufacturing. Europe maintains strong demand through Germany, France, Italy, Spain, the United Kingdom, and broader European quality expectations, with adoption shaped by EMA oversight, EU GMP expectations, advanced therapy activity, and rising sustainability scrutiny around disposable plastics.

The Middle East is emerging through GCC investments in pharmaceutical localization, with Saudi Arabia and the United Arab Emirates prioritizing healthcare security, vaccine access, and biomanufacturing capability. Africa is earlier in adoption but increasingly relevant as regional vaccine manufacturing, fill-finish capacity, workforce development, and technology-transfer initiatives develop in markets such as South Africa, Egypt, Rwanda, Senegal, and Morocco.

Key Group Insights

ASEAN markets are increasingly relevant for single-use bioprocessing because Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines are building biotechnology, vaccine, and pharmaceutical manufacturing ecosystems. The group's advantage lies in regional trade connectivity, growing healthcare demand, government support for life sciences investment, and the ability to serve both clinical-stage and commercial manufacturing needs through flexible, modular bioprocessing infrastructure.

The GCC is using healthcare diversification strategies to build local production capacity, reduce import dependency, and support vaccine and biologics access, while the European Union provides a highly regulated and innovation-oriented environment shaped by EMA oversight, EU GMP expectations, pharmacovigilance discipline, and sustainability policy. BRICS countries are important because Brazil, Russia, India, China, and South Africa combine large patient populations with rising biopharmaceutical manufacturing ambitions, biosimilar activity, public health programs, and policy support for localized production.

G7 countries remain central to technology development, regulatory precedent, advanced therapy commercialization, and high-value biologics manufacturing. NATO members, many of which overlap with G7 and EU economies, also influence biomanufacturing resilience through supply-chain security, pandemic preparedness, strategic stockpiling, dual-use manufacturing readiness, and defense-adjacent medical countermeasure programs.

Key Country Insights

The United States leads in biologics innovation, CDMO capacity, regulatory science, and cell and gene therapy commercialization, while Canada benefits from vaccine investments, academic translation, and growing domestic biomanufacturing capability. Mexico is strengthening pharmaceutical manufacturing links with North American supply chains and nearshoring strategies, and Brazil remains Latin America's most important biologics and public-health production market, supported by vaccine capabilities and biosimilar demand.

In Europe, the United Kingdom supports advanced therapy development, clinical manufacturing, and regulatory flexibility, Germany anchors engineering, automation, high-specification bioprocess equipment demand, and biologics manufacturing, and France is expanding vaccine and biologics capacity. Italy and Spain are important for contract manufacturing, injectable drug production, and sterile processing, while Russia maintains localized biologics ambitions despite geopolitical, financing, and supply constraints affecting access to advanced components and validation support.

In Asia-Pacific, China has scaled biologics and biosimilar development rapidly with expanding domestic manufacturing capability, India combines vaccine leadership with biosimilar production and CDMO growth, and Japan emphasizes quality, automation, process control, and specialty biologics. South Korea has become a global biologics manufacturing hub with strong large-scale biomanufacturing capabilities, and Australia supports clinical-stage biomanufacturing, translational research, advanced therapy development, and regional supply resilience.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize a dual-sourcing strategy for critical single-use assemblies, films, filters, connectors, tubing, bags, and sensors. Supplier qualification must extend beyond price to include resin traceability, change-notification discipline, extractables and leachables packages, particulate controls, business continuity planning, and regional logistics resilience.

Manufacturers should also build quality-by-design frameworks that integrate closed processing, standardized assemblies, validated automation, operator training, and real-time data capture. Sustainability should be addressed through lifecycle assessment, waste segregation, take-back programs where available, responsible incineration or recycling routes where technically feasible, and facility designs that quantify reductions in water, energy, cleaning chemicals, and cleaning validation effort.

Research Methodology

This executive summary is developed using secondary research grounded in recognized public sources and industry standards, including regulatory guidance from FDA, EMA, WHO, ICH, USP, ISO, and pharmacopeial frameworks relevant to single-use systems. It also considers published industry practices from bioprocessing associations, GMP expectations, technology-transfer guidance, and documented technology adoption across biologics, vaccines, biosimilars, and advanced therapies.

The analysis applies a triangulated approach that reviews demand drivers, manufacturing trends, regional policy signals, supply-chain considerations, regulatory expectations, and technology maturity. Insights are validated against observable industry behavior, including capacity expansions, CDMO strategies, quality-system requirements, and the operational characteristics of single-use bioreactors, filtration, mixing, storage, aseptic sampling, sterile connectors, and closed transfer systems.

Conclusion

Single-use bioprocessing is becoming a core enabler of flexible, scalable, and contamination-controlled biomanufacturing. Its role is expanding as biologics pipelines diversify and manufacturers seek faster facility deployment, smaller campaign footprints, reduced cleaning burden, and improved multiproduct agility.

The next phase of industry adoption will depend on disciplined quality management, resilient supplier ecosystems, AI-enabled process intelligence, and credible sustainability practices. Organizations that combine single-use platforms with validated automation, regional supply strategies, robust regulatory documentation, and lifecycle-based waste management will be best positioned to capture long-term operational value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Single-use Bioprocessing Market, by Offering

• 7.1. Individual Components
  • 7.1.1. Bags & Containers
  • 7.1.2. Connectors
  • 7.1.3. Filtration & Separation Devices
  • 7.1.4. Pumps & Flow Control
  • 7.1.5. Sampling Devices & Accessories
  • 7.1.6. Sensors & Probes
  • 7.1.7. Tubing
    • 7.1.7.1. Polyethylene (PE)
    • 7.1.7.2. Polypropylene (PP)
    • 7.1.7.3. Polyvinyl Chloride (PVC)
    • 7.1.7.4. Silicone
• 7.2. Single-Use Subassemblies
  • 7.2.1. Bioreactor / Process Assemblies
  • 7.2.2. Media Transfer Assemblies
  • 7.2.3. Sampling Assemblies
  • 7.2.4. Tubing Assemblies / Manifolds

8. Single-use Bioprocessing Market, by Workflow Stage

• 8.1. Downstream Processing
• 8.2. Fill-Finish Operations
• 8.3. Quality Control & Analytics
• 8.4. Upstream Processing

9. Single-use Bioprocessing Market, by Bioprocess Mode

• 9.1. Batch
• 9.2. Fed-Batch
• 9.3. Perfusion

10. Single-use Bioprocessing Market, by Single-use Subassemblies

• 10.1. Aseptic Transfer Sets
• 10.2. Filling Subassemblies
• 10.3. Manifold Assemblies
• 10.4. Sampling Subassemblies
• 10.5. Tubing Assemblies

11. Single-use Bioprocessing Market, by Manufacturing Processes

• 11.1. 3D Printing
• 11.2. Adhesive Bonding
• 11.3. Blow Molding
• 11.4. Extrusion
• 11.5. Injection Molding
• 11.6. Overmolding
• 11.7. RF Welding
• 11.8. Thermoforming
• 11.9. Ultrasonic Welding

12. Single-use Bioprocessing Market, by Application

• 12.1. Aseptic Filling
• 12.2. Cell Culture
• 12.3. Filtration
• 12.4. Mixing
• 12.5. Purification
• 12.6. Sampling
• 12.7. Storage

13. Single-use Bioprocessing Market, by End User

• 13.1. Academic & Research Institutes
• 13.2. Contract Manufacturing Organizations & Contract Research Organizations
• 13.3. Pharmaceutical & Biotechnology Companies

14. Single-use Bioprocessing Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Single-use Bioprocessing Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Single-use Bioprocessing Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. AdvantaPure by NewAge Industries
• 18.2. Agilitech
• 18.3. Aseptic Group
• 18.4. Avantor, Inc.
• 18.5. Bionet Servicios Tecnicos SL
• 18.6. BioPharma Dynamics Ltd.
• 18.7. CellBios Healthcare & Lifesciences Pvt. Ltd.
• 18.8. Compagnie de Saint-Gobain
• 18.9. Corning Incorporated
• 18.10. Cytiva by Danaher Corporation
• 18.11. Entegris, Inc.
• 18.12. Eppendorf SE
• 18.13. Foxx Life Sciences
• 18.14. Freudenberg Group
• 18.15. Getinge AB
• 18.16. Kuehne + Nagel International AG
• 18.17. Lonza Group AG Ltd.
• 18.18. Meissner Corporation
• 18.19. Merck KGaA
• 18.20. Mettler-Toledo International Inc.
• 18.21. Parker-Hannifin Corporation
• 18.22. PBS Biotech, Inc.
• 18.23. PharmNXT Biotech
• 18.24. PSG Dover by Dover Corporation
• 18.25. Repligen Corporation
• 18.26. SaniSure
• 18.27. Sartorius AG
• 18.28. Satake Multimix Corporation
• 18.29. Single Use Support GmbH
• 18.30. Tekni-Plex, Inc.
• 18.31. Thermo Fisher Scientific Inc.
• 18.32. Watson-Marlow Fluid Technology Solutions by Spirax Group PLC